Flying The Web For News.
  • 2024 Presidential Election
    2024 Presidential Election
  • Career Exam Study
    Career Exam Study
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News
+ Larger Font | - Smaller Font
Share

Globe NewsWire News Distribution Service


Ad hoc announcement pursuant to Art. 53 LR Basel, October 29, 2024 – Novartis announced today that Scemblix® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP).


Posted: 2024-10-29 19:03:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.



Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile - Newscast

Novartis’ Scemblix gains FDA approval for leukaemia

Wed, 30 Oct 2024 04:46:00 GMT Novartis has received US Food and Drug Administration (FDA) accelerated approval for Scemblix (asciminib) to treat adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid ...

Novartis gets FDA okay for frontline use of Scemblix in CML

Wed, 30 Oct 2024 03:48:00 GMT Novartis has picked up a new FDA approval for its chronic myeloid leukaemia therapy Scemblix that it believes is critical to unlocking the drug's blockbuster sales potential. First-in-class STAMP ...

Novartis' Scemblix Receives Accelerated FDA Approval For Newly Diagnosed Ph+ CML In Adults

Tue, 29 Oct 2024 19:37:00 GMT Novartis (NVS) announced that Scemblix (asciminib) was granted accelerated approval by the US Food and Drug Administration for adult ...

Novartis says Scemblix FDA approved in newly diagnosed CML

Tue, 29 Oct 2024 16:11:00 GMT Novartis (NVS) announced that Scemblix was granted accelerated approval by the U.S. Food and Drug Administration for adult patients with newly ...

Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile

Tue, 29 Oct 2024 12:28:00 GMT Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...


Blow Us A Whistle